Overview
The objective of the study is to evaluate, in a clinical trial, the efficacy of peri operative administration of long-acting inhaled ß-2 mimetics on the occurrence of postoperative pulmonary complications
Eligibility
Inclusion Criteria:
- Adult (\>18 years)
- Lung cancer eligible for surgical management by lung resection (non-small cell lung carcinoma = NSCLC) by any route
- Naïve to long-term inhaled bronchodilator therapy
- High risk of post-operative pulmonary complications (Pre-operative FEV1 \< 80%)
Exclusion Criteria:
- Patient refusal
- Pregnancy
- Emergency surgery
- Patient with a physiological status of WHO IV or ASA ≥ IV
- Asthma
- Patients treated with long-acting bronchodilators
- Severe heart failure (NYHA IV), unstable ischaemic heart disease (angina or recent infarction \< 3 months), obstructive hypertrophic cardiomyopathy, subvalvular aortic stenosis, severe uncontrolled hypertension Recent stroke \< 3 months
- High-grade unresponsive conductive disorders or unstable arrhythmia
- Thyrotoxicosis, pheochromocytoma
- Unbalanced diabetes
- Hypersensitivity to ß-2 mimetics or lactose
- Current participation in a trial of another drug therapy